Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma.
about
Targeting CDK6 in cancer: State of the art and new insightsA kinase-independent function of CDK6 links the cell cycle to tumor angiogenesisGenome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma.Modulation of microRNA expression in human lung cancer cells by the G9a histone methyltransferase inhibitor BIX01294.Recurrent amplification at 7q21.2 Targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator.Cyclin-dependent kinase 6 phosphorylates NF-κB P65 at serine 536 and contributes to the regulation of inflammatory gene expression.A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.Targeting cell cycle regulators in hematologic malignancies.Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma.CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia.Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis.Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disordersTargeted inhibition of the COP9 signalosome for treatment of cancerGenome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.Let-7a functions as a tumor suppressor in Ewing's sarcoma cell lines partly by targeting cyclin-dependent kinase 6.Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study.Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).GSK3-SCF(FBXW7) targets JunB for degradation in G2 to preserve chromatid cohesion before anaphase.Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells.miR-9 induces cell arrest and apoptosis of oral squamous cell carcinoma via CDK 4/6 pathway.
P2860
Q26796499-1237FE5D-C35F-44DC-9AF1-FF261C2E3E18Q28296641-145295BC-A45F-4B4D-8AD5-1705B5C8EBABQ33377270-2D187107-F42B-407F-8BA2-E54F4FEF4995Q33688613-25560CE9-E64A-4A11-97DD-605CF5583A8DQ33727680-1173399F-7A0E-460B-8D7B-52F8AC05D1BFQ34220592-3F8D89F6-F696-4B91-B4FC-066E269A2E46Q34540259-0F792EE3-07ED-4742-BACA-00AEDA95C87AQ34687067-48011C86-281A-45D0-9121-8622AD422232Q35177212-8F4F70E6-A0E7-4F4E-817F-690F3B90C15CQ35334436-42EB0F7C-5580-4D9D-ABCD-78C02A31B284Q36079202-49097A0C-65C3-4201-A66C-F9FF6A9B0BFDQ36869358-61E540C3-1DE9-40B2-A83C-E05D31836382Q37037268-37A33220-9F95-4190-A320-9A015195225CQ37085216-D37F10F3-5FF1-46BE-981E-0DF2C1DFDBB3Q37171576-73F39712-7032-4F9F-83F7-A1CA099DF284Q37364323-C1F2AC51-11CE-4D17-B1E1-DDF772AC4B99Q37401031-9E3ECDDA-FB8D-40EC-BF2C-8C40D19C0651Q37617616-66BA37EA-9FCB-43D1-A145-A6A6742CA27EQ38538589-FF10F076-CF2C-45C7-8BEB-781C580C1D44Q38616175-92210295-E32D-427D-8C97-0B03DEA59E01Q38832541-648621BC-EBEF-4DF0-A2E7-8D2A56F851CCQ38852024-44966FFC-59E2-427E-8A35-540BC7E724B0Q38949247-8042E774-7156-4AE0-B195-56BF54D81448Q39329020-BAADD9AD-2937-4406-B1A2-2758FD4153A9Q39620024-DD6D0520-F8D8-40EA-AADB-48D91A840AC5Q47599483-A06A4F13-95B3-4666-97E3-F57C68D1C601
P2860
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma.
@en
type
label
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma.
@en
prefLabel
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma.
@en
P2093
P2860
P356
P1433
P1476
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma.
@en
P2093
Kaufmann M
MacLeod RA
Quentmeier H
Rosenwald A
P2860
P2888
P304
P356
10.1038/SJ.LEU.2405028
P577
2007-11-08T00:00:00Z
P5875
P6179
1008354984